MarketInOut Stock Screener Log In | Sign Up

Dimerix Ltd

Healthcare • Biotechnology • Quote as of 10/29/2026 16:10
Dimerix Ltd stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
Market Capitalization120.08 mln
Float456 mln
Earnings Date03/01/2027

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

4.26
Highly suspicious

Relative Strength

74 / 100
Outperforming

Pre-Tax Margin

-840%
Severely loss-making

ROE

363
Extraordinary

Altman Z-Score

-3.01
Deeply distressed

Business Description

Dimerix is an Australian medical research company focused on creating treatments for serious conditions that currently lack effective solutions. Its main programs include therapies targeting rare kidney diseases, diabetic kidney complications, and severe respiratory conditions linked to COVID-19. The company also holds a unique drug-testing technology that helps identify how medications interact with the body. Dimerix operates from its base in Fitzroy, Australia.

Key Fundamentals

EPS-0.05
ROE363
RPS0.01
ROIC-98.94
ROA-41.73
EBITDA, mln-36.54
EV / EBITDA-3.34
EV / EBIT-3.34
Revenue, mln4.35
EV / Revenue28.08

Quote Details

Last 0.215
Change 0.01 (4.88%)
Open 0.21
Volume 462,081
Turnover 99,347
Average Volume 506,666

Financial Ratios

Pre-Tax Profit Margin-840
Current Ratio3.82
Price / Sales28.75
PEG Ratio0.72

Financial Strength

Altman Z-Score-3.01
Piotroski F-Score 3 / 9
Beneish M-Score4.26

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 4.88% 86 / 100   
1 Month -6.52% 42 / 100   
2 Months -10.42% 33 / 100   
6 Months -10.42% 42 / 100   
1 Year -58.25% 12 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog